EMA Recommends Extension of Indications for Trastuzumab Emtansine
New indication concerns adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1631 results
Secondary Surgical Cytoreduction Followed by Chemotherapy vs Chemotherapy in Recurrent Ovarian Cancer
The results of the GOG-0213 study
Clinical Benefit of Pembrolizumab in Previously Treated Advanced MSI-H/dMMR Non-colorectal Cancers
The results of KEYNOTE-158 study
Divergent HLA Allele Linked to Immunotherapy Efficacy
Researchers uncover how immune checkpoint inhibitor response relies on the evolved efficiency of HLA-mediated immunity
FDA Approves Luspatercept-aamt for Anaemia in Patients with Beta Thalassemia
Evidence for efficacy is based on the results from the BELIEVE trial
Cancer-Related Cognitive Impairment in Cancer Survivors
Detection and management strategies
Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
The results of the AcSé phase II study
Efficacy and Biomarker Analysis of Neoadjuvant Immune Checkpoint Blockade in Urothelial Cancer
Findings from the ABACUS trial
Gilteritinib for Relapsed or Refractory FLT3-Mutated AML
Results from the phase III randomised trial
Pembrolizumab as a Combination or Monotherapy in First-line Treatment for Recurrent or Metastatic HNSCC
The results from KEYNOTE-048 study
Discovery of AMG 510, a First in Class Oral KRAS G12C Inhibitor
Preclinical evidence and anti-tumour activity in the first dosing cohorts in patients with KRAS G12C mutated cancer
EMA Guide on Biosimilars for Healthcare Professionals Available Now in 23 Official EU Languages
The guide is updated in October 2019